BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: A meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4559-4570

  Li, Carol ^a   Lee, Kathleen C ^a   Schneider, Eric B ^a   Zeiger, Martha A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADVANCED CANCER; AGE; ARTICLE; BRAF GENE; CANCER INVASION; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER STAGING; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTIPLE CANCER; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; SEX DIFFERENCE; THYROID PAPILLARY CARCINOMA; TUMOR CAPSULE; TUMOR VOLUME;

AGE FACTORS; AMINO ACID SUBSTITUTION; CARCINOMA; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; HUMANS; LYMPHATIC METASTASIS; MALE; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; SEX CHARACTERISTICS; THYROID NEOPLASMS; TUMOR BURDEN; VALINE;

EID: 84870733693     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2104     Document Type: Article

References (48)

1. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS 2009 Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 18:784-791
2. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306 (Pubitemid 28065257)
3. Handkiewicz-Junak D, Czarniecka A, Jarzab B 2010 Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol 322:8-28
4. Mazzaferri EL 2009 What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)? Oncology (Williston Park) 23:579-588
5. Randolph GW 2010 Papillary cancer nodal surgery and the advisability of prophylactic central neck dissection: primum, non nocere. Surgery 148:1108-1112
6. Zeiger MA, Dackiw AP 2005 Follicular thyroid lesions, elements that affect both diagnosis and prognosis. J Surg Oncol 89:108-113 (Pubitemid 40315906)
7. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397 (Pubitemid 37153748)
8. Lee JH, Lee ES, Kim YS 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110:38-46
9. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE 2006 Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222 (Pubitemid 43740191)
10. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P 2010 Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95:4197-4205
11. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R 2008 BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15:191-205 (Pubitemid 351449739)
12. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M 2009 Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 94:1612-1617
13. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D, Hoon DS 2006 Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 244:799-804 (Pubitemid 44629955)
14. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P 2004 BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61:239-243 (Pubitemid 39093120)
15. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89-97
16. Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE 2009 Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146:1215-1223
17. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R 2009 BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977-2982
18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB 2000 Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008-2012 (Pubitemid 30214957)
19. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T 2007 Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27:3645-3649 (Pubitemid 47607514)
20. Pelizzo MR, Boschin IM, Barollo S, Pennelli G, Toniato A, Zambonin L, Vianello F, Piotto A, Ide EC, Pagetta C, Sorgato N, Torresan F, Girelli ME, Nacamulli D, Mantero F, Mian C 2011 BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor.Amono-institutional experience. Clin Chem Lab Med 49:325-329
21. So YK, Son YI, Park JY, Baek CH, Jeong HS, Chung MK 2011 Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol Head Neck Surg 145:422-427
22. Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR 2009 Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 253:854-860
23. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT 2005 No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 63:461-466
24. Oler G, Cerutti JM 2009 High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 115:972-980
25. Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, Zhang Y, Cheng W, Zhao W 2009 Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 16:240-245
26. Xing M, Tufano RP, Tufaro AP, Basaria S, Ewertz M, Rosenbaum E, Byrne PJ, Wang J, Sidransky D, Ladenson PW 2004 Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 89:2867-2872 (Pubitemid 38766378)
27. Czarniecka A, Rusinek D, Stobiecka E, Krajewska J, Kowal M, Kropiñska A, Zebracka J, Kowalska M, Włoch J, Maciejewski A, Handkiewicz-Junak D 2010 Occurrence of BRAF mutations in a Polish cohort of PTC patients: preliminary results. Endokrynol Pol 61:462-466
28. Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M 2006 Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 91:3667-3670 (Pubitemid 44402153)
29. Jung CK, Kang YG, Bae JS, Lim DJ, Choi YJ, Lee KY 2010 Unique patterns of tumor growth related with the risk of lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 23:1201-1208
30. Kim KH, Suh KS, Kang DW, Kang DY 2005 Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 55:540-545
31. Kim SK, Song KH, Lim SD, Lim YC, Yoo YB, Kim JS, Hwang TS 2009 Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 19:137-141
32. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK 2006 The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65:364-368
33. Lee JH, Lee ES, Kim YS, Won NH, Chae YS 2006 BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 38:201-204 (Pubitemid 43879713)
34. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM 2010 The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294-3300
35. Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K 2007 Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathol Int 57:12-20 (Pubitemid 44934914)
36. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943-3949
37. - targeting to the membrane. Endocr Relat Cancer 13:257-269
38. Sapio MR, Posca D, Troncone G, Pettinato G, Palombini L, Rossi G, Fenzi G, Vitale M 2006 Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 154:341-348
39. Sykorova V, Dvorakova S, Ryska A, Vcelak J, Vaclavikova E, Laco J, Kodetova D, Kodet R, Cibula A, Duskova J, Hlobilkova A, Astl J, Vesely D, Betka J, Hoch J, Smutny S, Cap J, Vlcek P, Novak Z, Bendlova B 2010 BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest 33:318-324
40. Goutas N, Vlachodimitropoulos D, Bouka M, Lazaris AC, Nasioulas G, Gazouli M 2008 BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 28:305-308 (Pubitemid 351362917)
41. O'Neill CJ, Bullock M, Chou A, Sidhu SB, Delbridge LW, Robinson BG, Gill AJ, Learoyd DL, Clifton-Bligh R, Sywak MS 2010 BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148:1139-1145; discussion 1145-1136
42. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567 (Pubitemid 36951030)
43. Shackelford W, Deng S, Murayama K, Wang J 2004 A new technology for mutation detection. Ann NY Acad Sci 1022:257-262 (Pubitemid 38951612)
44. Morris LG, Shaha AR, Tuttle RM, Sikora AG, Ganly I 2010 Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid 20:153-158
45. Leung AK, Chow SM, Law SC 2008 Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope 118:32-38
46. Lang BH, Lo CY, Chan WF, Lam AK, Wan KY 2006 Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg 30:752-758 (Pubitemid 43724102)
47. Elsheikh TM, Asa SL, Chan JK, DeLellis RA, Heffess CS, LiVolsi VA, Wenig BM 2008 Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 130:736-744
48. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK 2005 The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol 63:588-593 (Pubitemid 41626756)